Novogen subsidiary to list in London
10 May, 2002 by Daniella GoldbergNovogen's US subsidiary, Edward Marshall, plans to list on the Alternative Investment Market of the London Stock Exchange at the end of the month.
Prima reports 100 per cent success in cancer trial
10 May, 2002 by Tanya HollisA treatment to encourage the immune systems of cancer patients to attack the disease has proven 100 per cent effective in early stage results.
Cryosite makes ASX debut
09 May, 2002 by Daniella GoldbergAustralia's first for-profit tissue banking service company, Cryosite, listed on the ASX today (May 9).
Bionomics in licensing deal with J&J
09 May, 2002 by Tanya HollisSouth Australian genomics research company Bionomics (ASX: BNO) has entered a licensing deal with Johnson & Johnson Research (JJR) to develop angiogenesis drugs.
Public invited to have a say on GM cotton
09 May, 2002 by Melissa TrudingerThe Australia and New Zealand Food Authority (ANZFA) has invited public comment on its proposal to approve the use of a new version of Monsanto's genetically modified Bt-Cotton.
La Trobe research developing allergy-free ryegrass
07 May, 2002 by Daniella GoldbergMelbourne-based researchers are developing a transgenic rye grass that will reduce the risk of hay fever in allergy sufferers.
Peptech to profit in UK
07 May, 2002 by Daniella GoldbergPeptech will reap further profits from its Remicade anti-TNF antibody in Britain.
BioDiem appointment ramps up market bid
06 May, 2002 by Tanya HollisDrug development company BioDiem has appointed a pharmaceutical industry heavyweight to its board in the lead-up to a public listing this year.
Work begins on Chemeq plant
06 May, 2002 by Iain ScottPerth-based research pharma Chemeq (ASX: CMQ) has begun work on its $25 million production facility at Rockingham, in the city's south.
Aust officials 'negative' on global GM protocol
06 May, 2002 by Melissa TrudingerAustralia has no plans to sign an international protocol covering the environmental impact of trade in living genetically modified organisms (LMOs), with trade officials calling for more discussion on how it would affect grain trade.
Analysts explain ResMed share tumble
06 May, 2002 by Tanya HollisInvestors have lost patience with companies failing to deliver on expectations, analysts said today (Monday, May 6), with ResMed the latest stock hit by their wrath.
Radioactive agreement for Sirtex
03 May, 2002 by Daniella GoldbergSirtex Medical has entered into an agreement with German-based AEA Technology, a supplier of radioactive products, to assist in distributing its SIR-Spheres internationally.
ResMed plummets after earnings warning
03 May, 2002 by Iain ScottSleep disorder specialist ResMed's shares took a beating on the Australian Stock Exchange this morning (May 3), dropping more than 22 per cent when the company suggested that it would not be able to meet its fourth quarter earnings estimate.
Genetic manipulation to free Murray-Darling of carp
02 May, 2002 by Melissa TrudingerCSIRO scientists have hatched an ambitious plan to wipe out carp in the Murray-Darling River, by using genetically manipulated carp that lack the ability to change sex.
BresaGen to build new research facility
02 May, 2002 by Daniella GoldbergAdelaide-based company BresaGen has received $8.9 million from the South Australian government to build a new research facility at the Thebarton Biotechnology Precinct.
